Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Xray Volume Imaging (Cone Beam CT) - Prostate Cancer

This study has been completed.
Sponsor:
Collaborators:
Abbott-CARO Uro-Oncologic Radiation Award
Princess Margaret Hospital, Canada
Information provided by:
University Health Network, Toronto
ClinicalTrials.gov Identifier:
NCT00188799
First received: September 12, 2005
Last updated: NA
Last verified: September 2005
History: No changes posted

September 12, 2005
September 12, 2005
November 2003
Not Provided
To evaluate he feasibility of daily X-ray volume imaging during conformal radiotherapy.
Same as current
No Changes Posted
To provide preliminary data concerning the relative utility of daily X-ray volume image matching compared to fiducial marker image matching.
Same as current
Not Provided
Not Provided
 
Xray Volume Imaging (Cone Beam CT) - Prostate Cancer
A Clinical Study of X-Ray Volume Imaging to Evaluate the Daily Set-Up Accuracy of Conformal Prostate Radiotherapy

Conformal dose escalated radiotherapy was adopted as the standard treatment technique at PMH for intermediate risk patients with localised disease in 1997. This technique provides a much smaller margin of error for treatment set-up and delivery than with conventional techniques. One way to ensure the accuracy of treatment delivery is to image the prostate position daily, prior to therapy, to allow for appropriate set-up corrections. To do so, imaging markers are implanted into the prostate under guided ultrasound (a standard procedure at PMH). However, there are disadvantages in using imaging markers which include added time to the treatment planning process, and an invasive procedure with a potential for discomfort, bleeding and infection. This study will investigate and compare X-ray volume imaging to the gold standard imaging markers.

Not Provided
Interventional
Phase 2
Allocation: Non-Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Prostatic Neoplasms
Procedure: daily Xray volume imaging for planning radiotherapy
Not Provided
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
30
November 2004
Not Provided

Inclusion Criteria:

  • Diagnosis of adenocarcinoma of the prostate
  • Patient undergoing escalated dose conformal external beam radiotherapy.
  • Patient has low or intermediate risk prognostic factors: all of PSA <21, Gleason score <8, clinical T category <T3, clinical N category 0 or X, M category 0 or X.
  • Informed consent

Exclusion Criteria:

  • No diagnosis of adenocarcinoma of the prostate
  • Patient not undergoing escalated dose conformal radiotherapy
  • Patient does not have low or intermediate risk prognostic factors
Male
18 Years and older
No
Contact information is only displayed when the study is recruiting subjects
Canada
 
NCT00188799
UHN REB 03-0483-CE, Abbott-CARO Uro-OncologicAward
Not Provided
Not Provided
University Health Network, Toronto
  • Abbott-CARO Uro-Oncologic Radiation Award
  • Princess Margaret Hospital, Canada
Principal Investigator: Charles Catton, MD Princess Margaret Hospital, Canada
University Health Network, Toronto
September 2005

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP